Rosemont Pharmaceuticals to acquire Aytu BioPharma for $2.70 a share in cash
The all-cash tender offer, announced November 16, 2026, carries premiums over recent trading prices, with closing expected by year end.
SEC filing
3 stories
The all-cash tender offer, announced November 16, 2026, carries premiums over recent trading prices, with closing expected by year end.
SEC filing
Aytu BioPharma posted higher net revenue on EXXUA growth while disclosing a definitive merger agreement with Rosemont Pharmaceuticals Holdings for $2.70 per share in cash.
SEC filing
EXXUA brought in $3.9 million in fourth-quarter net revenue and $6.6 million for the fiscal year, while legacy ADHD and pediatric brands declined amid generic competition.
SEC filing